Evaluation of association of mutation in ARID family of genes with outcomes in cutaneous melanoma


George P. Souroullas1, Tolulope Adeyelu2, Andrew Elliott2, Soo J. Park3, Kevin Kim4, Ari Vanderwalde2, George Ansstas1

Key Findings:

  • Melanoma patients with ARID mutations exhibited higher prevalence of markers associated with immune checkpoint inhibitor response, including TMB-H, PD-L1 and immune-related signatures.
  • Our data also suggests improved survival outcome in patients with ARID2 mutations, although no additional OS benefit was observed with anti-PD-L1 therapy.